Overview OTO-313 in Subjects With Subjective Tinnitus Status: Completed Trial end date: 2020-05-29 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety, tolerability, plasma pharmacokinetics (PK), and exploratory efficacy of OTO-313 administered as an intratympanic injection for the treatment of subjective tinnitus. Phase: Phase 1/Phase 2 Details Lead Sponsor: Otonomy, Inc.